Oryzon announces presentation of final data from PORTICO, vafidemstat’s global Phase IIb ... 26/06/2024 Healthcare Access to innovation Rare diseases Advanced therapies Seleccionada para presentación oral. La conferencia se celebrará en Milán del 21-23 de septiembre. Partners - Oryzon Genomics
ORYZON presents preliminary data from ongoing Phase Ib FRIDA trial with iadademstat plus ... 14/06/2024 Healthcare Access to innovation Drug discovery Rare diseases Data from the first two cohorts demonstrated that combination of iadademstat plus gilteritinib was safe and showed... Partners - Oryzon Genomics
Oryzon announces journal publication of final Phase IIa ALICE results with iadademstat in ... 03/06/2024 Healthcare Access to innovation Rare diseases Innovative drugs Advanced therapies The Phase IIa study ALICE evaluated the combination of iadademstat plus azacitidine in newly diagnosed, unfit patients... Partners - Oryzon Genomics
BCN HEALTH publishes a study estimating the cost of thalassaemia care across the world 29/05/2024 Healthcare Rare diseases BCN HEALTH desarrolló un modelo de costes aplicable a nivel mundial para la atención de la talasemia. Partners - BCN Health
Oryzon selected as Associated Partner in the first Important Project of Common European In... 29/05/2024 Healthcare Access to innovation Drug discovery Rare diseases Innovative drugs Personalized medicine Financing Commission has approved up to €1 billion of State aid by six Member States: Belgium, France, Hungary, Italy, Slovakia... Partners - Oryzon Genomics
Miramoon Pharma Receives Orphan Drug Designation for MP-004 28/05/2024 Healthcare Access to innovation Rare diseases Innovative drugs Orphan Drug Designation is a special status granted by the FDA to drugs that are intended to treat rare diseases or... Partners - Miramoon Pharma
Atlas Molecular Pharma successfully completes phase one in humans of its treatment for Con... 28/05/2024 Healthcare Access to innovation Drug discovery Rare diseases Innovative drugs Personalized medicine The final results of ATL-001, the biotech company's lead candidate, have shown that it is able to stabilize UROIIIS and... Partners - Inveready
BCN HEALTH will present several communications at the EASL and AASLD congresses evaluating... 27/05/2024 Healthcare Rare diseases The consulting firm specialized in the health sector will compare different quantitative data between patients suffering... Partners - BCN Health
Oryzon reports financial results and corporate update for quarter ended March 31, 2024 07/05/2024 Healthcare Access to innovation Rare diseases Personalized medicine Advanced therapies Financing Finalizing full data analysis from vafidemstat's PORTICO Phase IIb trial in Borderline Personality Disorder (BPD)... Partners - Oryzon Genomics
Mikrobiomik launches strategic investment round to advance its first medicine based on the... 30/04/2024 Healthcare Drug discovery Rare diseases Innovative drugs The Biscayan biopharmaceutical company, which plans to launch its first biological medicine into the market in the first... Partners - Mikrobiomik
